Abstract. A spectrophotometric method for the assay of human blood coagulation factor vIII in plasma is presented. The chromogenic assay for factor VIII:C in plasma is performed in 3 steps: (l) activation of factor VIII by thrombin; (2) activation of factor X in a mixture of factor X, factor IXa, phospholipids/Ca2t and plasma containing activated factor VIII, and (3) determination of the rate of factor Xa formation with the chromogenic substrate 52337. Within-assay variation was between 5 and 6.90/o for factor vIII:C activities between 20 and 1500/0. Clotting and chromogenic factor vIII:C actiyities were compared in plasma of 50 normal healthy donors (coefficient of correlation r: 0.g3).
Introduction
Factor VIII or anrihemophilia globulin A is a plasma protein that is essential for normal hemostasis (see [l] for review). Its congenital absence is by far the most common cause of congenital bleeding tendency. The procoagulant protein (factor VIII:C) occurs in plasma tightly bound to the von Willebrand factor (factor VIII:vWF). Factor VIII:C and vWF together form the factor VIII complex. Factor VIII:C appears responsible for normal thrombin formation, whereas factor VIII:vWF is required for platelet-vessel wall interaction. (For reviews on factor VIII complex and vWF see [2, 3] .) If factor VIII:C is congenitally deficient, factor VIII:vWF is normal. If factor VIII:vWF is deficient, factor VIII:C is to a varying degree also.
A widely used method to determine factor VIII in plasma is the l-stage clotting assay introduced in 1962 by Hardisty et al. [a] . This assay is based on the property of factor VIII to correct the prolonged clotting time of hemophiliac plasma to a degree determined by the amount of factor VIII present.
A new assay method for the determination of factor VIII using a chromogenic substrate for factor Xa appeared feasible after kinetic studies on the role of factor VIII in the intrinsic factor-X-activating complex [ 5] ' In this paper, we describe a spectrophotometric assay for factor VIII in human plasma and compare the properties and precision of the assay with the l-stage clotting assay.
Materials and Methods
S2 33 7, Bz-Ile-Glu(Piperidyl)-Gly-Arg-p-nitroanilide and S2238, H-D-Phe-Pip-Arg-p-nitroanilide were obtained from Kabi AB, Sweden. Egg-phosphatidylcholine (egg-PC) was from Koch-Light, UK, and brain-phospharidylserine (brain-PS) was from Sigma, St. Louis, Mo., USA. Hirudin was from Pentapharm' Basel, Switzerland. Fatty acid free human albumin and soybean trypsin inhibitor were obtained from Sigma. Factor-deficient plasmas were purchased from George King Biomedical, Overland Park, Kans', USA. The batch numbers used were factor VIII, GK 837-314; high molecular weight kininogen, GK 1603-D30; factor XII, GK 1202-921; factor XI, GK I I l0-Nl9; prekallikrein, GK 1704-124; passavoy GK 1501-625: factor V. GK 503-223, and von Willebrand, GK 1403-93. The factor-deficient plasmas from General Diagnostics were of the following lot numbers: factor VIII, 4G926', factor X, 4H699; factor VII, 4J759. Factor-Vlll-defrcient plasma (WH) and factor-IX-deficient plasma were obtained from local patients. Kaolin (light) was ftom Koch-Light. Inosithin was from Associated Concentrates, New York, USA.
Proleins
Bovine factor X (factor X2 was used in this work), factor IXa and thrombin were purihed and activated as published before [5] . Phospholipid vesicles consisting of 400/o brain-PS and 600/o egg-PC were made by sonication at 0'C in a buffer of 50mM tris-HCl, l75mM NaCl, pH 7.9, as described before [6] .
Human Donor Plasmas Blood was obtained from healthy volunteers after informed consent by venipuncture using a 1.2 X 40 mm needle, discarding the first 2 ml. Blood (9 ml) was mixed with I ml of O.l M trisodium citrate in a plastic tube and centrifuged for 30 min at 2,000 81. The plasma was aspirated and made platelet-free by a centrifugation at 4"C for 15 min at 14,000g in the Beckmann J-21 rotor. The plasma samples were frozen and stored at -70 'C in small portions. Reference pool plasma was made by mixing I ml of each of the donor plasmas (n : 50). It is assumed that factor VIII:C activity in the reference plasma is I U/ml. Different dilutions of the reference pool were used to obtain standard c-q reference curves.
Spectrophotometric Assay for Faclor VIII (Standard Factor VIII AssaY) Forty microliters of human plasma (or a sample in which factor VIII must be determined) is added to a prewarmed mixture of 910 pl buffer containing 175 mM NaCl, 50 mM tris-HCl, pH 7.9, 0.5 mg/ml human albumin and 50 pl of 60 nM (6 NIH U/ml) of thrombin. After incubation for I min at 37 " C, 500 ptl of the plasma, containing activated factor VIII, is added to a second tube containing 450 pl of a prewarmed (37 'C) mixture of phospholipids, CaCl2 and factor IXa. Factor X activation is started by addition to the reaction mixture of 50 pl of l0 pM factor X, at the same time as the activated plasma. Tbe final composition of the reaction mixture (1 ml) is: 20 pl of plasma, added as 500 pl thrombin-activated plasma; 0.5 1tM factor X, 50 nM factor IXa, 20 pM phospholipid vesicles (40molo/o PS/60 mol0/o PC); l.5nM thrombin, 0.5 mg/ml human albumin in a buffer containing 175 m-44 NaCl, 5O mM tris-HCl (pH 7.9) and 6mM CaClz.
After I and 2 min, samples from the reaction mixture (usually 0.1 ml) were added to a cuvette (37 "C) with 0.8 ml buffer of 175 m-l.1NaCl, 50 m,l'1tris-Hcl' pH 7.9, 2OnM EDTA, 0.5 antithrombin units of hirudin and 0.5 mglml human albumin. After addrtion of 0.1 ml 52337 (2.35mM;25 A316 units/ml), the absorbance increase at 405 nm was recorded for 2-3 min using a Beckman Model 25 spectrophotometer. From the absorbance change, the amount of factor Xa present was calculated using a calibration curve made with a factor Xa preparation of known concentration. The rate of factor Xa formation was calculated from the amount offactor Xa present after I and 2 min and was corrected for the rate found in'a blank experiment run without plasma.
Factor VIII Clotting AssaY A l-stage clotting assay for factor VIII [4] was carried out by preincubating for 6 min at 37 "C 50 pl factor-Vlll-deficient plasma, 50 pl kaolin-inosithin in Michaelis buffer, and 50 pl of the factor VIII sample.
After 6 min, 50 pl l/30 M CaClt was added to start clot formation. The clotting time was determined by tilting the tubes. The amount of factor VIII present was determined from a reference curve. This curve is a double logarithmic plot of the clotting times (determined in duplicate) of 10 different dilutions of reference plasma. The composition of Michaelis buffer was 0.0285 M Na acetate, 0,0285 M Na barbiturate, 0. I l6 M NaCl (pH 7.a). The kaolin-inosithin suspension contained 5 mg/ml kaolin and I mg/ml inosithin Statistical Analysis of Data The significance of differences between 2 values was tested by a paired Student t tesr. CV is the coet ficient of variation, the standard deviation is expressed as a percentage ofthe mean.
Results

Determination of Optimal Assay Conditions
In intrinsic factor X activation, factor X is cleaved to factor Xa by the enzyme factor IXa, and the rate of this reaction is strongly enhanced in the presence of the nonenzymatic accessory components, i.e. activated factor VIII and phospholipids. Factor VIIIa works by at least 2 different mechanisms: it increases the affinity of factor IXa for binding to phospholipids [7] by a factor ofabout 100 and it also increases the V-u* turnover number of factor Xa formation by factor IXa about 1,000-fold [5] . The experimental conditions for the factor VIII assay in plasma as described in 'Materials and Methods' were based on the observations done in purified systems [5, 7] . The factor X concentration in the assay (0.5 ttM) was chosen well above the K. for factor X (0.06 tt@. A phospholipid vesicle concentration of 20 pM was selected in the assay because the rate of factor Xa formation strongly increases between 0 and 5 pM, reaches a plateau between l0 and 50 1tM, and decreases at higher phospholipid concentration. The factor IXa concentration used in the assay is 50 n41 and is based on the experiment shown in figure l. The rate of factor Xa formation increases with the factor IXa concentration and levels off at higher factor IXa concentrations. In the absence of plasma factor VIII, a low rate of factor Xa formation proportional with factor IXa is found. When this rate is subtracted from the rate measured in the presence of plasma, a plateau level is obtained, indicating apparent saturation of the factor-X-activating system with factor IXa. A factor IXa concentration in the assay of 5OnM approaches saturation. When 20 pl plasma is present in the assay, the background rate without plasma is about 100/o of the rate measured in the presence of plasma.
Factor VIII must be activated before i1 can participate in factor X activation, and thrombin is a well-known activator of factor VIII. Activated factor VIII is not stabile and rapidly inactivates [2, 6] . Therefore, the activation of factor VIII in plasma by thrombin was carried out in a 1-min period just before the start ofeach factor X activation reaction. Optimal conditions for activation were established by the experiments shown in frgure 2. Plasma was incubated at varying thrombin concentrations and after I min, the activated plasma sample was transferred to a mixture of phospholipid, Ca2* and factor IXa. Simultaneous with the activated plasma, factor X was added and the time course of factor Xa formation was determined during 3 min. As shown in figure 2, no factor X activation is found within 3 min when thrombin is omitted from the plasma activation mixture. The rate of factor Xa formation increases when increased amounts of thrombin a1e used (0-1.8 nI4)to activate the Forty microliter of reference pool plasma was added to 960 pl of a prewarmed (37'C) solution of 3.0nM thrombin in a buffer containing 5OmM tris-HCl, l'/5mM NaCl, pH 7.9. and 0.5 mg/ml of human albumin After exactly I min at 37 "C, 500 pl of the plasma thrombin mixture was transferred to a second prewarmed tube containing 450 pl of a mixture of phospholipids, CaCl2 and varying amounts of factor IXa. Together with the activated plasma, 50 pl of factor X ( l0 p,tf) was added to start factor Xa formation. After I and 2 min, samples of 100 pl were added to prewarmed (37'C) cuvettes containing 0.8 ml of a buffer containing 50 mM trisHCl, 175mM NaCl, 20mM EDTA, pH 79, and, 0.5 mg/rnl human albumin. To the cuvette was added 0. I ml chromogenic substrate 52337 (2.35 m,rl4) . The absorbance change at 405 nm was measured and used to calculate the amount of factor Xa present as described in 'Materials and Methods'. The composition of the factor-X-activating mixture of I ml was: 20 pl human plasma, 1.5 n,]ly'thrombin, 20 pMphospholipid vesicles consisting of40 0/o phosphatidylserine and 60 0/o phosphatidylcholine, factor IXa as indicated in the figure,0.5 pMfactor X, 50 mMtris-Hcl, 175 m,4,1NaCl, 6 mM CaCl1 pH 7 .9, and 0.5 mg/ml human albumin r : Without plasma; r : with reference pool plasma; o: difference curve obtained by substraction.
factor VIII present. No further increase (or decrease) in the time course of factor Xa formation was observed at thrombin concentrations between 1.8 and 6 n 11. This result suggests that optimal activation of factor VIII in plasma is obtained under these conditions. The amounts of thrombin did not influence the factor Xa generation by a factor-Vlllindependent mechanism, as no aclivity was observed when factor VIII was absent (frg. 1) (see also below). Hence, in the standard assay procedure, plasma is activated for I min at a thrombin concentration of 3 nM. The time course of factor Xa formation was linear for at least 2 min, and the rate of factor Xa formation was calculated from the amount of factor Xa present after I and 2 min.
Hirudin is present in the cuvettes to inhibit the activity of thrombin on the chromogenic substrate 52337. Thrombin is formed from prothrombin present in the plasma sample during the factor X activation reaction. In the standard factor VIII assay containing 20 pl plasma, 27 nM thrombin is formed after 2 min. The thrombin concentration was determined using 52238 as the chromogenic substrate for thrombin in a cuvette that contained soybean trypsin inhibitor to inactivate factor Xa. Addition of hirudin (0.5 antithrombin units per cuvette) inhibited the thrombin activity on 52238 for 97.80/0. A much larger Fig.2 . Determination of the optimal thrombin concentration for the activation of factor VIII in human plasma Pool plasma (40 pl) was added to 960 pl of a buffer (37 "C) containing 50 m,tltris-HCl, 175mM NaCl, pH 7.9, 0.5 mg,/ml human albumin and varying amounts of thrombin (0-6 nM\ as indicated. After I min, 500 pl of the thrombin-aclivated plasma was transferred to a reaction mixture for factor X activation, as described in the legend of figure l. The rate of factor Xa formation was as determined as in figure I from the amounts of factor Xa present after I and 2 min. The final composition of the reaction mixture ( I ml) was: 20 pl human plasma, 20 pM phospholipid, 50 nM facror IXa, 0.5 pM factor X, 50 mM tris-HCl, 175 mM NaCl, 6 mM CaCl2, pH 7.9, and 0.5 mg/ml human albumin.
excess of hirudin (5-50 antithrombin units per cuvette) could not be used, since the hirudin preparation partially inhibited the activity of factor Xa on 52337. When in the standard factor VIII assay hirudin was omitted from the cuvettes, 3.2 + 2.4o/o (mean + SD; n: I I l), higher rates of factor X activation were found, indicating that the contribution of thrombin to the total hydrolysis of 52337 is relatively small. Properties of the Spectrophotometric Assay Linearity of the Assay. Varying amounts of reference pool plasma were added to our standard test system. As shown in hgure 3, a linear dependence between the rate offactor Xa formation and the plasma concentration is found between 5 and 30 pl of plasma per milliliter reaction mixture. High amounts of plasma in the assay give rise to clot forma- Fig.3 . Linearity of the assay. V2rying amounts of reference pool plasma were incubaled with 1.0 nM of thrombin in I ml.
After I min at 37'C. 500 ul of the mixture was transfcrrcd to 500 ul ofa reaclion mixture for factor X activation. The amounl of factor Xa formed was determined after I and 2 min, as described in the legcnd of figure I The reaction mixture with the amounls of activated plasma as indicated contained I 5 nM thrombin and further components for faclor X activation as described in the lcgend offigure 2. An amount of20 pl ofreference pool plasma in the factor X activalion mixture was chosen as the condition for the standard factor VIII assay, the rate of factor Xa formation found was desisnated as the I U/ml value. tion in the factor X activation mixture, which prevents accurate sampling. In the low range, a slight deviation from linearity is found. The same line is seen when the plasma samples are diluted in factor-Vllldeficient plasma. In the standard factor VIII assay, an amount of 20 pl plasma per milliliter reaction mixture is present. If values of below 200/o of normal are to be expected in the abnormal sample, the sample volume is increased so as to ensure the equivalent amount of at least 2 pl of normal plasma factor VIII in the test.
To demonstrate that the spectrophotometric assay depends on factor VIII and not on other clotting factors, we determined the factor VIII activity with the 2 assays in various factor-deficient plasmas. The results shown in table I indicate that background activity is measured in 3 different factorVlll-deficient plasmas and in plasma. of a patient with severe von Willebrand's disease. All other plasmas show factor VIII activities in the 2 assays comparable to the activities of normal individuals (frg. 4). This Between-assay precision of the chromogenic assay was determined by use of the reference pool plasma, stored in small portions aI -70 "C. On l0 consecutive days, I portion was assayed, from which the between-assay Fig.4 . Comparison of factor VIII activity determined by chromogenic and by clotting assay in 50 normal individuals. Blood was collected from healthy volunteers. Plasma preparation and the assays for factor VIII were carned out as described in 'Materials and Methods'. For 50 normal samoles: v: 0.0883 + 0.949x', r:0.82. variation was calculated. Considerably smaller assay variations are observed from the chromogenic factor VIII assay than for the factor VIII clotting assay.
Comparison of the Chromogenic Method with the Clotting Assay -Variation in Factor VIII Activity in Normal Individuals. We determined factor VIII activity with the chromogenic method and the clotting assay in plasma of 50 healthy volunteers (30 men and 20 women). The results are shown in figure 4 . The coefficient of correlation between the 2 assay methods is 0.82. The mean, the range and the interindividual variation for the 2 assays are presented in table III. No significant differences in factor VIII activity were observed between males and females. The I U/ml value of factor VIII in the chromogenic assay represents 20 pt of human reference pool plasma in the final reaction mixture of I ml. The 1000/o value in the clotting assay is defined as the clotting trme obtained when 0.1 ml ofa l:20 dilution ofthe reference pool plasma is clotted in a l-stage clotting assay for factor VIII with a final reaction volume of 0.4 ml. Reference pool plasma was obtained from 50 subjectively healthy donors (30 men, 20 women). Within-assay variation: coeffrcient of variation for measurements on the same day. Between-assay variation: coefficient of variation for measurements on different days. 
Discussion
In this paper, a spectrophotometric method for the determination of factor VIII in human plasma is presented. The method is based on the role of factor VIII as a nonenzymatic cofactor in intrinsic factor X activation. The assay consists of 3 steps: (1) incubation for I min of plasma (or a sample containing factor VIII) with thrombin to conyert factor VIII to factor VIIIa; (2) incubation for 2 min of factor VIIIa with factor IXa, factor X and phospholipid./Ca2* to allow factor Xa formation, and (3) determination of the amount of factor Xa in samples taken after I and 2 min. Factor Xa is measured with the chromogenic substrate 52337 in the presence of EDTA to stop further factor X activation. The rate of factor Xa formation is calculated and compared to the rate found with reference plasma. Factor VIII activity is expressed in units per milliliter, assuming that the factor VIII activity in reference pool plasma is I U/ml.
The components used in the chromogenic assay are bovine clotting factors IXa, X and thrombin that were prepared by standard procedures and commercial available phos_ pholipids. Saturating (excess) concentrations of factors IXa, X and phospholipids were chosen to minimize variations due to a slight activity change that might occur in these preparations.
Factor VIII was activated in a separate step at an optimal concentration of throm_ bin. When thrombin was omitted, no mea_ surable amount of factor Xa is formed within the assay period of 2 min. Factor Xa formation starts after 5-6 min, presumably as a result offactor VIII activation by traces of factor Xa and./or thrombin formed during the lag period. The frnding that optimal fac_ tor VIII activation by thrombin could be obtained suggests that all factor VIII is converted to factor VIIIa. Consequently, the as_ say responds to the total concentration of factor VIII, irrespective of the activity state of factor VIII. By performing the factor VIII assay without thrombin, it might be possible to detect circulating factor VIIIa. The few plasma samples we have tested so far without thrornbin showed no evidence for a pres_ ence of factor VIIIa.
The rate of factor Xa formation we find in plasma (3 nM Xalmin) is proportional to the plasma factor VIII concentration and can be used to calculate the plasma factor VIII concentration. The thrombin activation experiments and the factor IXa saturation curve indicate that all plasma factors VIII participate in factor X activation. When it is assumed that factor VIII functions in a oneto-one stoichiometrical complex with factor IXa in the enzymatic unit, then the rate of factor Xa formation is proportional to the concentration of the limiting component in the complex, which is here the factor VIIIa concentration.
The maximal rate of factor Xa formation is 925 mol Xalmin/mol enzyme. This indicates that 3.0/925 nM factor VIII is present in the reaction mixture. In the assay, plasma is diluted l:50, and hence, the plasma VIII concentration in plasma is 150/925 0.16 nM + 320/0. This value is in agreement with estimates by immunological methods
I2l.
The sensitivity of the chromogenic assay extends to plasma factor VIII levels of about 0.05 U/ml, but at factor VIII concentrations of 0.10U/ml and lower, the coefficient of variation increases. Low levels of factor VIII can be detected by including larger sample volumes in the reaction mixture. When factor VIII is determined in plasma, not more than 40 pl plasma can be used if fibrin formation in the factor X activation mixture may preyent accurate sampling to the cu_ vette. Defibrination by Arvin is useful in that case. The absorbance change found after 2 min of factor Xa formation under standard conditions (20 pl plasma per milliliter reac_ tion mixture and 100 pl sample per cuvette) is 0.0210 AA405/min. Up to lO-fold higher absorbance changes when a larger fraction of the reaction mixture is transferred to the cuYette.
The coefficient of variation of the chro_ mogenic assay varies between 5-7o/o. where_ as the precision of the clotting assay varies between 17 and 2lo/o. The same large assay variations of the clotting method have : been observed in previous studies [4, 8, 9] . The diversity in reagents, methods and equipment that is used in clotting assays may account for the large inter_laboratory variation observed in factor VIII determinations [0] . Introduction of the chromogenic assay with its superior reproducibility may allow standardization.
A spectrophotometric assay for factor VIII has been presented by Ros6n et al. [1 l, l2l working at KabiVitrum Diagnostica. Details of their assay have not been disclosed, but as the assay presented here, their method is based on the factor X activation reaction. The precision and sensitivity of the Kabi assay is similar to ours.
Several groups have used immunoradiometric assays to quantify factor-Vlllcoagulant antigen in plasma [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Human allogeneic antibodies are used in these assays obtained from hemophilia A patients with circulating anti-VIII:C antibodies that developed after infusions of factor VIII preparations or from individuals that developed these antibodies spontaneously. The radioimmune assays are very sensitive and have been used to detect factor VIII levels of 0.01-0.03 U/ml. The method depends on the availability of the antibodies which may prevent large-scale application; moreover, immunological methods are complicated by the fact that immunologically recognized factor VIII:C may not be functionally active in clotting reactions [13] .
Factor VIII in normal individuals varied between 0.53 and 2.27 Ulml, what results in a variation in normals of 29.7 o/o. Previously, we found a variation for factors VII, IX, X and prothrombin of 21. 4, 11.0, 15.0, and 12.0o/o, respectively I I 8] , suggesting that the factors VII and VIII present in plasma in the lowest concentration and the shortest halflife tend to have the largest biological variatron.
Factor VIII assays are carried out to detect hemophilia, to identify carriers of hemophilia, to check the potency of factor VIII preparations used to treat hemophilia and to control treatment.
For prenatal diagnosis of hemophilia [4] , the assay can easily be scaled down such that the test can be carried out with small plasma volumes obtained by fetoscopy lt7, l8l.
